Philip Tsai Purchases 12,300 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was bought at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the transaction, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This represents a 58.57 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Immunome Stock Performance

Shares of IMNM stock opened at $7.09 on Thursday. The firm has a market capitalization of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93. Immunome, Inc. has a one year low of $6.94 and a one year high of $26.70. The company has a 50 day moving average price of $9.61 and a 200 day moving average price of $11.41.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on IMNM shares. Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective on the stock. Guggenheim decreased their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $25.50.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Immunome during the 4th quarter worth about $70,000. KLP Kapitalforvaltning AS acquired a new position in Immunome during the fourth quarter valued at approximately $75,000. AlphaQuest LLC grew its stake in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after buying an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its stake in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in shares of Immunome in the 4th quarter valued at $95,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.